A Phase 2B Randomized Double-Blind Placebo-Controlled Multiple Dose Multicenter Study to Assess Efficacy and Safety of SER 287 in Adults with Active Mild-to-Moderate Ulcerative Colitis

Brief description of study

The purpose of this study is to obtain safety and efficacy (how well something works) information of an investigational agent, SER-287 on your Ulcerative Colitis. SER-287 is considered investigational because it is still being tested in research studies and is not Food and Drug Administration (FDA)-approved for treatment purposes. Ulcerative Colitis (UC) is a condition causing chronic inflammation of the surface of the colon, leading to episodes of bloody diarrhea, urgency and abdominal (belly) pain. The cause of the disease is not known, but some think it may be a combination of how environmental factors interact with your genetics, immune responses and gut bacteria (also known as your gut “microbiome”). The gut microbiome consists of trillions of bacteria that live in the human gastrointestinal tract. These bacteria help control the immune system. Studies have shown that the gut microbiome of patients with UC may be different from the gut microbiome of patients without UC.

Clinical Study Identifier: s18-00432
ClinicalTrials.gov Identifier: NCT03759041
Principal Investigator: David P Hudesman.
Other Investigator: Shannon Chang.

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.